Veeva attracts top talent in clinical operations and clinical data
management
PLEASANTON, Calif.--(BUSINESS WIRE)--
Veeva
Systems (NYSE:VEEV) today announced it continues to grow its
clinical leadership team with the addition of five industry veterans in clinical
operations and clinical
data management.
“Veeva is focused on delivering the best clinical products in the market
on one unified cloud platform,” said Peter Gassner, founder and CEO of
Veeva Systems. “This mission is attracting the most widely respected
people from across the industry with deep domain expertise and a
consistent track record of innovation.”
New members of Veeva’s clinical team include:
Raymond
Letulle, senior vice president, Veeva Vault EDC – Raymond
has more than 25 years of experience in enterprise software. Prior to
Veeva, he was chief operating officer and head of products at Medrio,
responsible for product strategy and running the product management and
design teams for the company’s eClinical products, including EDC and
eSource. In his role at Veeva, Raymond will lead the development of Vault
EDC and Vault
eSource, delivering the technology innovation that customers need to
improve speed and data quality and cut the cost and complexity in
clinical trials.
Ami
Dudzinski Mehr, vice president of services, Veeva Vault EDC –
Ami has nearly 20 years of experience in professional services spanning
life sciences, research and development, and consulting. She has
extensive software and delivery methodology expertise in implementing
SaaS-based EDC and IRT/IVRS for Phase I-IV clinical trials. She most
recently led the services team for EDC at Oracle. At Veeva, Ami is
responsible for the Veeva Vault EDC Global Services team and ensuring
delivery excellence, quality, and speed for customers.
Hugo
Cervantes, vice president, Veeva Vault EDC – Hugo is
responsible for Vault EDC strategy, market adoption, and customer
engagement. He has spent the last 15 years in management consulting and
professional services, helping biopharmaceutical R&D organizations
increase their productivity, innovate, and grow. Prior to Veeva, Hugo
was senior director, corporate strategy at QuintilesIMS and held senior
management roles at Deloitte and Accenture. His earlier career was spent
implementing across biopharma EDC for Phase Forward.
Jason
Rizzo, senior director of sales, Veeva Vault EDC – Jason brings
nearly 20 years of life sciences experience to Veeva, where he leads the
EDC sales team. Recognized for building customer-centric and inquisitive
sales teams, Jason combines his broad expertise in eClinical
applications with deep domain knowledge in the drug development
functions of clinical data management and clinical operations. Prior to
joining Veeva, Jason held multiple roles at Medidata Solutions,
including vice president of platform sales.
Henry
Galio, senior director, Veeva Vault CTMS – Henry is involved in
developing the strategy for Vault
CTMS. He has nearly 25 years of experience in the enterprise
software industry and 20 years of experience in clinical, implementing
more than 50 CTMS projects and advising approximately 200 life sciences
clients on CTMS. Most recently, Henry was senior director of clinical
for Oracle, where he led a group of solutions architects creating cloud
service offerings for CTMS and CDA.
Connect with the Veeva clinical team on LinkedIn:
Ray
Letulle
Ami
Dudzinski Mehr
Jason
Rizzo
Hugo
Cervantes
Henry
Galio
Additional Information
For more on Veeva Vault Clinical
Suite, visit: veeva.com/clinical
Connect
with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 525 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended April 30, 2017. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170613005575/en/
Source: Veeva Systems Inc.